BIIB-021

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBIIB-021
Drug Alias NameBIIB-021CNF-2024CF-1983 mesylate
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat shock protein HSP90 inhibitors
TargetsHeat shock protein HSP90
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsGastrointestinal Stromal Tumors +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesRussian Federation +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursBreast NeoplasmsGastrointestinal Stromal Tumors +[6] 

Other Information

ATC CodeN/A
Related LinksN/A